SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap is trending amid excitement surrounding a new partnership with Perplexity AI, which includes a $400 million deal and integration of AI search into Snapchat. The community is discussing the potential for this deal, combined with a stock buyback program, to signal a turnaround and re-rate the stock, especially given Snap's large user base and AI initiatives. Some traders are anticipating a short squeeze and upgrades from analysts.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending as investors anticipate potential catalysts from the upcoming earnings call, with community chatter focused on a possible buyout or partnership announcement, especially with AstraZeneca, given their aligned earnings release date and recent facilities transaction. Some traders are positioning for a short squeeze due to high short interest and a decrease in available shares to borrow, while others express skepticism and frustration with management's past performance. The broader context involves speculation around the future of COVID-19 vaccines and Novavax's role in the evolving market.

Duolingo, Inc. is a language-learning website and mobile application, which engages in the development of a free language learning website and crowd sourced text translation platform. It offers Duolingo for Schools, a free, web-based tool that aims to make it easier for teachers to use the Duolingo platform in a structured learning environment, and English Test, an online, on-demand assessment of English proficiency. The company was founded by Luis von Ahn and Severin Hacker in 2011 and is headquartered in Pittsburgh, PA.

Duolingo Inc - Ordinary Shares - Class A

Duolingo Inc

Duolingo ($DUOL) is trending as investors debate the impact of AI on its language learning platform. While some fear free AI translation apps could disrupt their business, others argue that language learning is irreplaceable and see long-term value, especially with growing revenue and user numbers. Community discussions also revolve around the recent stock drop following earnings, with some viewing it as a manipulation and buying opportunity.

Avantis is the largest RWA perps DEX in DeFi, built on and backed by Base. Avantis allows users to trade crypto and real-world assets (RWAs), including FX, commodities, indices, and equities. Backed by Pantera and Coinbase, Avantis is the largest DEX on Base by volumes, and brings institutional-grade products to DeFi, letting users trade with up to 500x leverage in a transparent, permissionless environment.  Avantis is best known for launching zero-fee perpetuals (ZFP) — a first-of-its-kind primitive where traders only pay fees if they profit. They've also brought leveraged RWAs onchain. This has driven explosive growth: over $20B+ in cumulative volume and 15M+ run-rate revenues since Febrruary 2024.

Avantis

Avantis ($AVNT) is trending as the community debates its potential amid discussions of buybacks and token unlocks scheduled for February. Some investors express concerns about competitor influence, particularly from $BNB and $ASTER, while others champion $AVNT as a Coinbase-backed project with a live buyback dashboard and locked developer tokens. Traders are watching key price levels, anticipating volatility and potential for a short squeeze.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

CELH is trending as investors anticipate upcoming earnings, with many expecting a positive report driven by strong growth and the Alani Nu acquisition. The community is actively discussing potential price targets and whether the stock will experience a post-earnings surge, while also debating the impact of potential market manipulation. Sentiment remains largely bullish, with some viewing any dips as buying opportunities ahead of earnings.

Figma, Inc. is an AI-powered design platform that enables seamless collaboration across the entire product development lifecycle. Its products include FigJam, Figma Slides, Figma Design, Figma Draw, Dev Mode, Figma Sites, Figma Buzz and Figma Make. The company was founded by Dylan Joseph Field and Evan Darrow Wallace in 2012 and is headquartered in San Francisco, CA.

Figma Inc. - Ordinary Shares - Class A

Figma

Figma is trending as investors assess the impact of recent earnings and guidance, with debates focusing on long-term profitability and growth potential. Community members are weighing the company's AI integration and potential for a short squeeze against concerns about valuation and lock-up periods. The stock's performance relative to peers and broader market trends is also a key talking point.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid is trending as the EV maker announced partnerships with both Uber and Nvidia, generating bullish sentiment. The community is discussing the potential for Lucid to achieve Level 4 autonomous driving and the possibility of a short squeeze. Despite the positive news, concerns remain around profitability, upcoming earnings, and potential dilution.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is trending as analysts weigh in following recent earnings and amid some volatility related to data privacy concerns and short-seller reports. The community is actively discussing price targets, potential SEC investigations, and the company's growth prospects in the mobile gaming and e-commerce sectors, with some anticipating a continued climb while others remain cautious.

$SWEAT is the beating heart of the Movement Economy—a groundbreaking token that transforms physical activity into real-world value. Minted through movement, $SWEAT rewards your steps with a crypto asset that you can earn, trade, or grow. The team states that their app has increased their users’ physical activity by an average of 20%, creating a healthier society and reducing burdens on global healthcare systems. With over 20 million holders, SWEAT is eliminating barriers and making Web3 accessible to everyone, one step at a time.

Sweat Economy

Sweat Economy is trending as the community anticipates a potential breakout, emphasizing its long-term potential. Many users are highlighting the ability to earn crypto through walking and staking, though others are wary of the token's price action. Community members are also excited about the US launch of Sweat Wallet.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

GRRR is trending as investors discuss the company's potential in AI-driven infrastructure and smart city solutions, fueled by significant contracts and growing institutional confidence. Community members highlight the favorable risk-reward asymmetry and upcoming earnings as potential catalysts. Some traders express frustration with recent price action, while others remain optimistic about the long-term prospects and potential acquisition.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ESPR Aims to Diversify With Rare Liver Disease Candidate, Stock Up

Esperion selects ESP-2001 as a preclinical candidate for primary sclerosing cholangitis, a rare liver disease, aiming to begin clinical studies in 2026.

ESPR Stock Drops 17% on Pricing of $75M Common Stock Offering

Esperion's stock sinks after pricing its common stock offering at $2.50 per share, a 19% discount to the prior close.

Shares of Esperion Therapeutics tumbled almost 20% in premarket trading on Wednesday after the cholesterol drugmaker moved to raise fresh capital through a steeply discounted stock sale.The company priced its new offering at $2.50 per share, about 19% below Tuesday’s closing price of $3.09. Esperion expects to raise roughly $75 million from the sale of 30 million shares, with an option for underwriters to buy an additional 4.5 million shares over the next month. The deal is expected to close around Oct. 9.Meanwhile, Morgan Stanley, Piper Sandler, and Cantor Fitzgerald are leading the offering, joined by Citizens JMP Securities, H.C. Wainwright, and Needham &amp; Company as co-managers. Esperion said the proceeds will go toward expanding commercialization of its non-statin cholesterol treatments and strengthening its financial position.The fundraising effort comes after the Michigan-based biotech firm notched a legal win protecting its core cholesterol-lowering drugs. Last week,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/esperion-shares-rally-after-patent-litigation-settlement-for-cholestrol-drugs/chCujWhR3Qb">Esperion reached a settlement with Dr. Reddy’s Laboratories</a>, ensuring the Indian pharma company cannot market generic versions of Nexletol and Nexlizet in the U.S. before April 19, 2040.That settlement followed similar agreements with Micro Labs USA, Hetero USA, and Accord Healthcare, effectively shoring up Esperion’s patent on bempedoic acid, the key ingredient in both drugs, through December 2030.On Stocktwits, retail sentiment for Esperion was ‘bullish’ amid ‘high’ message volume.One retail trader said the real question now is whether Esperion will use the new funds wisely, whether to repay debt and support its late-stage trials, rather than chase new acquisitions or side projects, which could signal poor capital discipline.<stembedurl>https://stocktwits.com/Sirius1026/message/631430171</stembedurl>Another user speculated that the timing of the offering hinted at deeper management motives, suggesting the cash crunch might be over and predicting a quick rebound above $3.<stembedurl>https://stocktwits.com/Rescueoncredit/message/631430163</stembedurl><a href="https://stocktwits.com/symbol/ESPR">Esperion’s stock</a> has risen 40.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Esperion’s stock (ESPR) has risen 40.5% so far in 2025. (Representative Image: Getty Images)

Why Is Esperion Therapeutics Stock Sinking Premarket Today?

The stock fell sharply in early trade after the cholesterol drugmaker priced its latest stock sale at a discount to Tuesday’s close.

Equity

ESPR Settles Nexletol/Nexlizet Patent Litigation With RDY, Stock Up

Esperion settles Nexletol and Nexlizet patent dispute with Dr. Reddy's, securing U.S. market exclusivity until 2040 and lifting its shares nearly 14%.

Esperion (ESPR) on Friday said that it has entered into a settlement agreement with Dr. Reddy’s Laboratories and its affiliate under which the latter has agreed not to market a generic version of either Nexletol or Nexlizet in the United States before April 19, 2040.The agreement <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/03/3160929/0/en/Esperion-Reaches-Settlement-Agreement-with-ANDA-Filer-Dr-Reddy-s-Laboratories-Not-to-Market-Generic-Versions-of-NEXLETOL-bempedoic-acid-and-NEXLIZET-bempedoic-acid-and-ezetimibe-Pr.html">resolves</a> the patent litigation brought by Esperion against Dr. Reddy’s Laboratories after it submitted an Abbreviated New Drug Application seeking approval to market a generic version of each of Nexletol and Nexlizet.The two drugs are used to reduce low-density lipoprotein (LDL) or "bad" cholesterol in adults with high blood cholesterol levels, known as primary hyperlipidemia. Shares of Esperion traded 8% higher in the pre-market session at the time of writing.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ESPR">ESPR stock</a> stayed within ‘neutral’ territory over the past 24 hours, while message volume remained at ‘normal’ levels.Esperion reached a settlement agreement with Micro Labs USA and its affiliate; Hetero USA, and its affiliates; and Accord Healthcare earlier this year with respect to their generic versions of Nexletol.The bempedoic acid portion of the two drugs is claimed in an Esperion patent scheduled to expire in December 2030, the company said. With the settlement with Dr. Reddy’s, there are no remaining challenges regarding the validity or infringement of the said patent in the pending patent litigation, it added.The company also stated that there is no assurance that the ongoing patent litigation against the remaining defendants, including Alkem Laboratories, will allow a generic version of the cholesterol drugs to be marketed in the U.S. before April 19, 2040.ESPR stock is up by 32% this year and by approximately 48% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ovid-therapeutics-stock-rally-pre-market-after-positive-results-from-trial-of-potential-seizure-treatment/chCuj8HR3Q2">Ovid Therapeutics Stock Rallied 18% Pre-Market – Here’s Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Esperion Shares Rally After Patent Litigation Settlement For Cholesterol Drugs

The company said that Dr. Reddy’s Laboratories has agreed not to market a generic version of either Nexletol or Nexlizet in the U.S. before April 19, 2040. 

Are Options Traders Betting on a Big Move in Esperion Therapeutics Stock?

Investors need to pay close attention to Esperion Therapeutics stock based on the movements in the options market lately.

ESPR's Q2 Earnings & Revenues Trump Estimates, Stock Rises

Esperion posts narrower-than-expected second-quarter loss with revenues rising 12% and product sales jumping 42% year over year.

Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of +88.24% and +24.28%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Crinetics Pharmaceuticals, Inc. (CRNX) Q2 Earnings Expected to Decline

CRINETICS PHARM (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Neurocrine Biosciences (NBIX) Q2 Earnings and Revenues Beat Estimates

Neurocrine (NBIX) delivered earnings and revenue surprises of +8.16% and +5.72%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The firm offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.

ESPR
Esperion Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ESPR News

ESPREsperion Therapeutics Inc.